Transfusion Medicine and Hemostasis

Clinical and Laboratory Aspects
 
 
Elsevier Science (Verlag)
  • 2. Auflage
  • |
  • erschienen am 13. Mai 2013
  • |
  • 1014 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-12-397788-5 (ISBN)
 

The second edition of Transfusion Medicine and Hemostasis continues to be the only 'pocket-size' quick reference for pathology residents and transfusion medicine fellows. It covers all topics in blood banking, transfusion medicine, and clinical and laboratory based coagulation. Short, focused chapters, organized by multiple hierarchical headings, are supplemented with up to 10 suggested reading citations. This single reference covers essentially all the topics required to meet the goals and objectives of a major program in transfusion medicine and clinical coagulation.

New chapters in the coagulation testing section reflect the development of new tests available and their incorporation into clinical practice. Coverage includes essential updates on the importance of new cellular therapies, peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in the understanding of molecular testing and pathogen reduction in two separate quality control chapters (one for blood centers and one for hospitals).


  • Updated content covers new coagulation tests, cellular therapies, and quality control issues
  • Easy to use, with focused, well-defined chapters in a standardized format throughout
  • Offers quick 'cross-reference' lists at the end of each chapter
  • Includes lists of common abbreviations and indexes that cross reference diagnostic, clinical and therapeutic commonalities
  • Englisch
  • Saint Louis
  • |
  • USA
  • 12,22 MB
978-0-12-397788-5 (9780123977885)
0123977886 (0123977886)
weitere Ausgaben werden ermittelt
  • Front Cover
  • Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects
  • Copyright
  • Contents
  • About the Editors
  • Contributors
  • Preface
  • Acknowledgments
  • Part I - Blod Banking and Transfusion Medicine
  • Chapter 1 - Blood Banking and Transfusion Medicine - History, Industry, and Discipline
  • History of Blood Transfusion
  • Discipline of Blood Banking and Transfusion Medicine
  • Centralized Transfusion Services
  • Structure of Blood Banks and Transfusion Services
  • Medical Specialty of Blood Banking and Transfusion Medicine
  • Recommended Reading
  • Chapter 2 - Quality Principles in Transfusion Medicine
  • Basic Principles
  • Quality Management Systems
  • Process Improvement
  • New Role of Quality
  • Recommended Reading
  • Chapter 3 - Regulatory Issues in Transfusion Medicine
  • Regulation versus Accreditation
  • The Food and Drug Administration
  • Laboratory Laws and Regulations
  • Other Regulatory Agencies
  • Recommended Reading
  • Chapter 4 - Role of the Physician in the Blood Center
  • Blood Center Table of Organization
  • Recommended Reading
  • Chapter 5 - Blood Donor, Donation Process and Technical Aspects of Blood Collection
  • Blood Donors
  • Blood Donation Process
  • Technical Aspects of Blood Donation
  • Recommended Reading
  • Chapter 6 - Apheresis Blood Component Collections
  • Apheresis RBC Collections
  • Plateletpheresis Collections
  • Plasmapheresis Collections
  • Recommended Reading
  • Chapter 7 - Recipient-Specific Blood Donation
  • Exceptional Medical Need
  • Directed Donation
  • Autologous Donation
  • Recommended Reading
  • Chapter 8 - Adverse Donor Reactions
  • Complications of Whole Blood Donation
  • Complications of Apheresis Donations
  • Approach to the Donor and Donation Process
  • Prevention
  • Biovigilance and Reporting
  • Recommended Reading
  • Chapter 9 - Component Preparation and Manufacturing
  • Whole Blood
  • Component Manufacturing
  • RBC Components
  • Plasma Components
  • Cryoprecipitate
  • Cryoprecipitate-reduced Plasma
  • Plasma Derivatives
  • Platelet Components
  • Granulocytes
  • Component Labeling
  • Recommended Reading
  • Chapter 10 - Serologic Testing of Donor Products
  • ABO Group Typing
  • D Antigen Phenotype
  • Antibody Screening for the Presence of Unexpected RBC Anti­bodies
  • Phenotyping RBC Products
  • Antibody Titer Anti-A, Anti-B
  • International
  • Recommended Reading
  • Chapter 11 - Overview of Infectious Disease Testing
  • Background
  • Approach to Testing
  • Determination of Need and Requirement for Testing
  • Selection of a Testing Methodology
  • Biology of an Infection, the Window Period and Testing Strategies
  • Product and Donor Management
  • Recommended Reading
  • Chapter 12 - Human Immunodeficiency Virus Screening
  • Description
  • Determination of Need and Requirement for Testing
  • Approach to Donor Testing
  • Blood Unit Management
  • Donor Management
  • International Considerations
  • Recommended Reading
  • Chapter 13 - Hepatitis B Viral Screening
  • Determination of Need and Requirement for Testing
  • Approach to Donor Testing
  • Donor Management
  • International Considerations
  • Recommended Reading
  • Chapter 14 - Hepatitis C Virus Screening
  • Determination of Need and Requirement for Testing
  • Approach to Testing
  • Donor Management
  • International Standards
  • Recommended Reading
  • Chapter 15 - West Nile Virus Screening
  • Determination of Need and Requirement for Testing
  • Approach to Testing
  • Donor Management
  • International Considerations
  • Recommended Reading
  • Chapter 16 - Syphilis, Human T-Cell Lymphotropic Virus, and Chagas Screening
  • Syphilis
  • Human T-Cell Lymphotropic Virus
  • Chagas' Disease
  • Recommended Reading
  • Chapter 17 - Bacterial Detection Methods
  • Methods to Avoid Bacterial Contamination
  • Methods to Reduce Bacterial Contamination
  • Methods to Inhibit or Inactivate Bacteria
  • Methods to Detect Contaminated Product
  • Methods Performed Just Prior to Product Release
  • Future Considerations
  • Recommended Reading
  • Chapter 18 - Role of the Transfusion Service Physician
  • Organization Chart
  • Specific TS Physician Roles
  • Transfusion Committee
  • Transfusion Practice Guidelines
  • TS Medical Direction within Small- to Medium-Sized Community ­Hospitals
  • Outsourced (Centralized) Transfusion Service
  • Transfusion Medicine as a Career
  • Recommended Reading
  • Chapter 19 - Pretransfusion Testing
  • Patient Identification
  • Pretransfusion Orders
  • Patient Specimen
  • Pretransfusion Testing
  • Blood Component Selection
  • Compatibility Testing (Crossmatch)
  • Labeling and Release of Blood Components
  • Special Clinical Situations
  • Quality Assurance
  • Recommended Reading
  • Chapter 20 - Antibody Identification
  • Clinical Significance of RBC Antibodies
  • Unexpected Antibody Identification
  • Determining Clinical Significance of Identified Antibody(ies)
  • Selection of Blood for Patients with Unexpected Antibody(ies)
  • Recommended Reading
  • Chapter 21 - Direct Antiglobulin Test
  • Indications
  • Specimen Requirement
  • Method
  • Evaluation of a Positive DAT
  • False Negative DAT
  • False Positive DAT
  • Recommended Reading
  • Chapter 22 - Molecular DNA Based Blood Group Typing
  • Manual Methods
  • Automated High-Throughput Methods
  • Discrepancies between Serology (Phenotype) and DNA (Genotype)
  • Applications of DNA-Based Molecular Testing
  • Recommended Reading
  • Chapter 23 - ABO and H Blood Group System
  • Antigens
  • Antibodies
  • Typing Discrepancies
  • Recommended Reading
  • Chapter 24 - Rh and RhAG Blood Group Systems
  • Antigens
  • Expression
  • Antibodies
  • Recommended Reading
  • Chapter 25 - Kell and Kidd Blood Group Systems
  • Kell Blood Group System
  • Kidd Blood Group System
  • Recommended Reading
  • Chapter 26 - MNS and Duffy Blood Group Systems
  • MNS Blood Group System
  • Duffy Blood Group System
  • Recommended Reading
  • Chapter 27 - Lewis, I, P1PK and GLOB Blood Group Systems
  • Lewis Blood Group System
  • Ii Antigens
  • P1PK and GLOB Blood Group Systems
  • Recommended Reading
  • Chapter 28 - Other Blood Group Systems, Collections, and Series
  • Other Potentially Clinically Significant Blood Group Systems
  • Other Blood Group Systems Sometimes Clinically Significant
  • Blood Group Systems Not Considered Clinically Significant
  • Blood Group Collections
  • High-Incidence RBC Antigens (901 Series)
  • Low-Incidence RBC Antigens (700 Series)
  • Chapter 29 - Human Platelet Antigens
  • Antigens
  • Disease Associations
  • Laboratory Diagnosis
  • Recommended Reading
  • Chapter 30 - HLA Antigens
  • HLA Antigens
  • Characteristics of the HLA System
  • HLA Matching
  • HLA Antibodies
  • HLA and Diseases
  • Recommended Reading
  • Chapter 31 - Red Blood Cell Products
  • Product Names
  • Description
  • RBC Storage Lesion
  • Indications
  • Laboratory Values as Transfusion Triggers and Guidelines for RBC Administration
  • Special RBC Products and Circumstances
  • Contraindications
  • Processing and Storage
  • Preparation and Administration
  • Dose
  • Adverse Events
  • Alternatives and Future Considerations
  • International Considerations
  • Recommended Reading
  • Chapter 32 - Plasma Products
  • Product Names
  • Brief History
  • Description
  • Indications
  • Dosage
  • Compatibility
  • Adverse Events
  • Alternatives to Plasma Products
  • International Considerations
  • Recommended Reading
  • Chapter 33 - Platelet Products
  • Product Names
  • Description
  • Indications
  • Preparation and Administration
  • Quality Assurance
  • Dose
  • Product Selection
  • Adverse Events
  • Alternatives and Future Considerations
  • International Standards
  • Recommended Reading
  • Chapter 34 - Cryoprecipitate and Fibrinogen Concentrates
  • Product
  • Description
  • Indications
  • Processing and Storage
  • Preparation and Administration
  • Cryoprecipitate Quality Assurance
  • Dose
  • Adverse Events
  • International Standards
  • Recommended Reading
  • Chapter 35 - Granulocyte Products
  • Description
  • Indications
  • Processing and Storage
  • Patient Selection, Dose Preparation, Administration, and Toxicities
  • Quality Assurance
  • International Issues
  • Recommended Reading
  • Chapter 36 - Albumin and Related Products
  • Albumin
  • Other Colloid Solutions
  • Recommended Reading
  • Chapter 37 - Human Immunoglobulin Preparations
  • Intravenous Immune Globulin
  • Hyperimmune Globulin Products (Hyper-Ig)
  • Recommended Reading
  • Chapter 38 - Rh Immune Globulin
  • Preparation and Administration
  • Indications of the Use of RhIg in the Prevention of Anti-D Formation
  • Indications of the Use of RhIg in ITP
  • Adverse events
  • International Standards
  • Recommended Reading
  • Chapter 39 - Coagulation Factor Products
  • Coagulation Factor Concentrate Production
  • Coagulation Factor Therapy Monitoring
  • Coagulation Factor Concentrate Dosing
  • Recommended Reading
  • Chapter 40 - Irradiation of Blood Products
  • Risk of TA-GVHD
  • Indications for Irradiated Products
  • Guidelines and Standards for Irradiation and Mitigation of TA-GVHD
  • Blood Products Requiring Irradiation
  • Processing and Storage
  • Quality Assurance
  • Adverse Events
  • International Considerations
  • Recommended Reading
  • Chapter 41 - Leukoreduction of Blood Products
  • Indications for Leukoreduction
  • Potential Indications
  • Controversial Indications
  • Contraindications
  • Methods of Leukoreduction
  • Quality Assurance
  • Prestorage versus Bedside Leukoreduction
  • Universal versus Diagnosis-Specific Leukoreduction
  • International Differences
  • Recommended Reading
  • Chapter 42 - CMV-Safe Blood Products
  • Description
  • Indications
  • Processing and Storage
  • Quality Assurance
  • Adverse Events
  • International Differences
  • Recommended Reading
  • Chapter 43 - Frozen Blood Products
  • Cryopreservation of RBC Products
  • Cryopreservation of Platelets Products
  • Cryopreservation of HPC Products
  • Recommended Reading
  • Chapter 44 - Washed Blood Products
  • Washing of RBC Products
  • Washing of Platelet Products
  • Indications
  • Recommended Reading
  • Chapter 45 - Volume Reduced Products
  • Volume Reduction of RBC Products
  • Platelet Products
  • Hematopoietic Progenitor Cell (HPC) Products
  • Recommended Reading
  • Chapter 46 - Pathogen Reduction Technologies
  • Need For Pathogen Reduction
  • Plasma
  • Platelets
  • Whole Blood
  • Conclusions
  • Recommended Reading
  • Chapter 47 - Neonatal and Pediatric Transfusion Medicine
  • Red Blood Cell (RBC) Transfusions
  • Platelet Transfusions
  • Plasma Transfusions
  • Cryoprecipitate Transfusions
  • Granulocyte Transfusions
  • Recommended Reading
  • Chapter 48 - Perinatal Transfusion Medicine
  • Hemolytic Disease of the Fetus and Newborn
  • Recommended Reading
  • Chapter 49 - Autoimmune Hemolytic Anemias
  • Clinical Manifestations
  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease
  • Combined Cold and Warm AIHA (Mixed AIHA)
  • Paroxysmal Cold Hemoglobinuria
  • Drug-Induced Hemolytic Anemia
  • Recommended Reading
  • Chapter 50 - Transfusion Management in Patients with Hemoglobinopathies
  • Sickle Cell Disease
  • Thalassemia
  • Recommended Reading
  • Chapter 51 - Transfusion of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation
  • Transfusion in the Patient Undergoing HSC Transplantation
  • Transfusion in Patients Undergoing Solid Organ Transplantation
  • Recommended Reading
  • Chapter 52 - Transfusion Management of Patients Receiving Antithrombotic Therapy
  • Venous Thrombosis Prophylaxis
  • Arterial Thrombosis Prophylaxis
  • Recommended Reading
  • Chapter 53 - Blood Transfusion in Economically Restricted and Developing Countries
  • Provision of Blood for Transfusion
  • Clinical Use of Blood
  • Conclusion
  • Recommended Reading
  • Chapter 54 - Management of Patients Who Refuse Blood Transfusion
  • Some Specific Circumstances Require Additional Consideration
  • Recommended Reading
  • Chapter 55 - Platelet Transfusion Refractory Patients
  • Non-Immune Refractoriness
  • Immune Refractoriness
  • ?Calculation of Refractoriness: The precise definition of platelet refractoriness varies, but one widely accepted definition is ...
  • Testing
  • Treatment of the Alloimmunized Patient
  • Bleeding, Platelet Refractory Patient
  • Recommended Reading
  • Chapter 56 - Massive Transfusion
  • Clinical Significance
  • Resuscitation Approaches
  • Massive Transfusion Protocols
  • Recommended Reading
  • Chapter 57 - Patient Blood Management
  • Minimizing Phlebotomy-Related Blood Loss
  • Treating Pre-Operative Anemia and Coagulopathy
  • Autologous Blood Conservation
  • Minimizing Peri-Operative Blood Loss
  • Minimizing Inappropriate Blood Use Through Evidence-Based ­Guidelines
  • Implementing Blood Management
  • Recommended Reading
  • Chapter 58 - Overview of Adverse Events and Outcomes Following Transfusion
  • Transfusion Reactions
  • Post-Transfusion Complications
  • Serious Hazards of Transfusion (NiSHOTs)
  • Recommended Reading
  • Chapter 59 - Febrile Non-Hemolytic Transfusion Reactions
  • Clinical Presentation
  • Incidence
  • Pathophysiology
  • Treatment
  • Prevention
  • Recommended Reading
  • Chapter 60 - Allergic Transfusion Reactions
  • Clinical Features
  • Pathophysiology
  • Treatment
  • Recommended Reading
  • Chapter 61 - Acute Hemolytic Transfusion Reactions
  • Incidence
  • Clinical Manifestations, Diagnosis and Evaluation
  • Pathophysiology
  • Management
  • Transfusion of ABO-incompatible RBCs
  • Transfusion of Non-ABO-Incompatible RBCs
  • Transfusion of Significant Amounts of Incompatible Plasma
  • Recommended Reading
  • Chapter 62 - Delayed Hemolytic Transfusion Reactions
  • Incidence
  • Clinical Manifestations
  • Pathophysiology
  • Diagnosis
  • Prevention
  • Hyperhemolytic Transfusion Reaction (HHTR)
  • Recommended Reading
  • Chapter 63 - Transfusion-Associated Circulatory Overload
  • Incidence
  • Clinical Manifestations
  • Pathophysiology
  • Diagnosis
  • Differential Diagnosis
  • Management
  • Prevention
  • Recommended Reading
  • Chapter 64 - Transfusion-Related Acute Lung Injury
  • Definition
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Differential Diagnosis
  • Management
  • Prevention
  • Recommended Reading
  • Chapter 65 - Septic Transfusion Reactions
  • Clinical Presentation and Management
  • Incidence and Implicated Bacteria
  • Sources of Contamination and Approaches to Prevention of Transfusion-Associated Septic Reactions
  • Summary
  • Recommended Reading
  • Chapter 66 - Metabolic, Hypotensive and Other Acute Reactions and Complications
  • Metabolic Complications of Transfusion
  • Hypotensive Reactions
  • Transfusion-Associated Dyspnea
  • Red Eye Syndrome
  • Back Pain
  • Recommended Reading
  • Chapter 67 - Post-Transfusion Purpura
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Prevention
  • Recommended Reading
  • Chapter 68 - Transfusion-Associated Graft-Versus-Host Disease
  • Transfusion-Associated Graft-Versus-Host Disease
  • Transfusion-Associated Microchimerism
  • Recommended Reading
  • Chapter 69 - Transfusion-Related Immunomodulation
  • Accepted TRIM Effects
  • Debated TRIM Effects
  • Proposed Mechanisms of TRIM
  • Potential Problems with TRIM Science
  • Recommended Reading
  • Chapter 70 - Iron Overload
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 71 - Transfusion-Transmitted Diseases
  • Hepatitis Viruses
  • Retroviruses
  • Herpesviruses
  • Other Viruses
  • Bacteria
  • Protozoa
  • Prions
  • Potential Emerging Infections
  • Recommended Reading
  • Chapter 72 - Overview of Therapeutic Apheresis
  • Principle
  • Methods
  • Vascular Access
  • Volume Exchanged and Frequency of TA
  • TA Calculation
  • Replacement Solutions
  • Anticoagulation
  • Adverse Events
  • ASFA Guideline for TA
  • Evaluation of a New Patient for the Initiation of TA
  • Recommended Reading
  • Chapter 73 - Therapeutic Plasma Exchange
  • Pathophysiology
  • Methods
  • Volume Exchanged
  • Timing and Frequency
  • Replacement Fluids
  • Anticoagulants
  • Adverse Events
  • Indications
  • Recommended Reading
  • Chapter 74 - Therapeutic Erythrocytapheresis
  • Volume Exchanged
  • End Hematocrit (Hct)
  • Replacement Fluids
  • Adverse Events
  • Indications
  • Recommended Reading
  • Chapter 75 - Therapeutic Thrombocytapheresis
  • Volume Exchanged
  • Replacement Fluid
  • Anticoagulant
  • Indication
  • Recommended Reading
  • Chapter 76 - Therapeutic Leukocytapheresis and Adsorptive Cytapheresis
  • Volume Exchanged
  • Frequency and Timing
  • Anticoagulant
  • Replacement Fluid
  • Indications
  • Recommended Reading
  • Chapter 77 - Extracorporeal Photopheresis
  • ECP Principles
  • Methods
  • Anticoagulant
  • Adverse Effects
  • Indications
  • Recommended Reading
  • Chapter 78 - LDL Apheresis
  • Volume Exchanged
  • Frequency and Timing
  • Anticoagulant
  • Adverse Effects
  • Indication
  • Recommended Reading
  • Chapter 79 - Immunoadsorption
  • Volume Exchanged
  • Adverse Effects
  • Indications
  • Recommended Reading
  • Chapter 80 - Therapeutic Phlebotomy
  • Indications
  • Recommended Approach
  • Recommended Reading
  • Chapter 81 - Overview of Cellular Therapy
  • Donors
  • Homologous versus Non-homologous Cells
  • Regulation of Cellular Therapies
  • Current Good Tissue Practices and Current Good Manufacturing Practices
  • Sources of Cells
  • Current Status
  • Recommended Reading
  • Chapter 82 - Hematopoietic Progenitor Cell Products Derived from Bone Marrow and Peripheral Blood
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Progenitor Cell Products
  • Donors
  • Preparative Regimens
  • Regulation of HPC
  • Processing and Derived Products
  • Cryopreservation and Storage
  • Thawing, Infusion, and Adverse Events
  • Recommended Reading
  • Chapter 83 - Cord Blood Banking
  • Cord Blood Banking
  • Types of Cord Blood Banking
  • Recommendations for Cord Blood Banking
  • Public Cord Blood Banking
  • National Cord Blood Inventory (NCBI)
  • Oversight and Regulatory Aspects of Public CB Banking
  • Recommended Reading
  • Chapter 84 - Regenerative Medicine
  • Definitions
  • Stem and Progenitor Cell Based Therapies
  • Tissue Engineering Approaches to Regenerative Therapy
  • Recommended Reading
  • Chapter 85 - Tissue Banking in the Hospital Setting
  • Tissue Suppliers
  • Hospital Tissue Services
  • Tissues Transplanted at Hospitals
  • Regulatory Agencies and Tissue Banking
  • Decentralized Tissue Services
  • Centralized Tissue Services
  • Responsibility of Hospital Tissue Services
  • Recommended Reading
  • Chapter 86 - Adverse Events associated with Hematopoietic Progenitor Cell Product Infusion
  • Incidence
  • Types of Reactions
  • Documentation and Reporting
  • Conclusion
  • Recommended Reading
  • Chapter 87 - Quality and Regulatory Issues in Cellular Therapy
  • Standards
  • Regulation
  • The Future
  • Recommended Reading
  • PART II - Hemostasis
  • Chapter 88 - Overview of the Coagulation System
  • Platelet/ Blood Vessel Interaction
  • Role of Platelets in Coagulation
  • Formation of Thrombin
  • Recommended Reading
  • Chapter 89 - Approach to the Bleeding Patient
  • Patient's History
  • Physical Examination
  • Laboratory Evaluation
  • Overview of Coagulation Testing
  • Recommended Reading
  • Chapter 90 - Congenital Thrombocytopenia
  • Diagnosis
  • Management
  • Congenital Thrombocytopenias
  • Recommended Reading
  • Chapter 91 - Fetal and Neonatal Alloimmune Thrombocytopenia
  • Pathophysiology
  • Clinical
  • Diagnosis
  • Management
  • Antenatal
  • Screening
  • Recommended Reading
  • Chapter 92 - Acquired Neonatal Thrombocytopenia
  • Pathophysiology
  • Clinical Presentation
  • Differential Diagnosis
  • Diagnosis of Acquired Thrombocytopenia
  • Management
  • Recommended Reading
  • Chapter 93 - Bernard-Soulier Syndrome and Other GPIb-IX-V Related Receptor Defects
  • Bernard-Soulier Syndrome
  • Benign Mediterranean Macrothrombocytopenia
  • Thrombocytopenia and Velocardiofacial (DiGeorge) Syndrome
  • Platelet-type von Willebrand Disease (Gain of Function Mutation of GPIb-IX-V)
  • Recommended Reading
  • Chapter 94 - Glanzmann Thrombasthenia
  • Pathophysiology
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 95 - Platelet Storage Granule Defects
  • Diagnosis
  • Management
  • Hermansky-Pudlak Syndrome
  • Chediak-Higashi Syndrome
  • Gray Platelet Syndrome(s)
  • White Platelet Syndrome
  • Other Granule Defects
  • Recommended Reading
  • Chapter 96 - Failure to Release and Aspirin-like Defects
  • Examples of Failure of Granule Release and Aspirin-like Defects
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 97 - Acute (Childhood) Immune Thrombocytopenia
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 98 - Chronic Immune Thrombocytopenia
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Differential Diagnosis
  • Management
  • Recommended Reading
  • Chapter 99 - Drug-Induced Thrombocytopenia
  • Pathology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 100 - Heparin-Induced Thrombocytopenia
  • Epidemiology
  • Pathophysiology
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 101 - Autoimmune Lymphoproliferative Syndrome
  • Pathophysiology
  • Genetics
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 102 - Hemolytic Uremic Syndrome
  • Pathophysiology
  • Diarrhea-Associated HUS
  • Clinical Manifestation and Laboratory Features
  • Diagnosis
  • Management/Prognosis
  • Recommended Reading
  • Chapter 103 - Thrombotic Thrombocytopenic Purpura
  • Pathophysiology
  • Epidemiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 104 - Antiphospholipid Syndrome
  • Diagnosis
  • Laboratory Measurement of aPL
  • Association between Different APL and Thrombosis
  • Pathogenesis
  • Clinical Features
  • Management of Patients with APS
  • Catastrophic APS
  • Future Directions
  • Recommended Reading
  • Chapter 105 - von Willebrand Disease
  • Pathophysiology
  • Overview of Molecular Variants and Prevalence
  • Clinical Manifestations
  • Diagnosis
  • Differential Diagnosis
  • Management
  • Recommended Reading
  • Chapter 106 - Hemophilia A
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Complications
  • Recommended Reading
  • Chapter 107 - Hemophilia B
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Complications
  • Recommended Reading
  • Chapter 108 - Congenital Disorders of Fibrinogen
  • Pathophysiology
  • Role in Coagulation
  • Genetics
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 109 - Factor XIII, a2-Antiplasmin and Plasminogen Activator Inhibitor-1 Deficiencies
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 110 - Factor XI Deficiency
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 111 - Factor VII Deficiency
  • Pathophysiology
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 112 - Factor II, Factor V and Factor X Deficiencies
  • Pathophysiology
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 113 - Bleeding Disorders in Pregnancy
  • Congenital Disorders
  • Acquired Disorders
  • Recommended Reading
  • Chapter 114 - Vascular Bleeding Disorders
  • Hereditary Vascular Malformations
  • Hereditary Connective Tissue Disorders
  • Acquired Vascular Disorders
  • Recommended Reading
  • Chapter 115 - Bleeding Risks with Liver Disease
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Differential Diagnosis
  • Management
  • Recommended Reading
  • Chapter 116 - Bleeding Risks with Vitamin K Deficiency
  • Pathophysiology
  • Clinical Manifestation
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 117 - Bleeding Risks with Cardiac Disease
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis and Differential Diagnosis of Bleeding Associated with CPB
  • Management
  • Recommended Reading
  • Chapter 118 - Bleeding Risks with Renal Disease
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 119 - Bleeding Disorders in Cancer Patients
  • Vascular Causes
  • Platelet Disorders
  • Coagulation and Fibrinolysis
  • Recommended Reading
  • Chapter 120 - Disseminated Intravascular Coagulopathy
  • Pathophysiology
  • Clinical Manifestations
  • Diagnosis
  • Management
  • Recommended Reading
  • Chapter 121 - Acquired Coagulation Factor Inhibitors
  • Inhibitors of FVIII
  • Inhibitors of vWF
  • Inhibitors of FV
  • Inhibitors of Prothrombin and Thrombin
  • Recommended Reading
  • Chapter 122 - Overview of Purposes of Hemostasis Testing and Common Sources of Error
  • Screening to Assess Risk of Hemorrhage in Otherwise Asymptomatic Patients Prior to an Invasive Procedure
  • Measuring the Effect of Hemostasis System-Modifying Drugs
  • Monitoring Hemostasis System Under Stress, and Assessing the Need for Replacement Products
  • Diagnostic Workup to Assess Risk of Recurrent Thrombosis or ­Bleeding in Patients with Unexpected Thromboembolic or Hemorrhagic ...
  • Sources of Diagnostic Errors in Hemostasis Testing
  • Recommended Reading
  • Chapter 123 - Thrombin Time and Fibrinogen Determination
  • Physiologic Role of Fibrinogen
  • Clinical Significance
  • Testing Overview
  • Recommended Reading
  • Chapter 124 - Prothrombin Time
  • Quick and Owren PT
  • International Normalized Ratio (INR)
  • Test Limitations
  • Test Interpretation
  • Recommended Reading
  • Chapter 125 - Activated Partial Thromboplastin Time
  • Test Utility
  • Test Limitations
  • Interlaboratory Variation
  • Pre-Analytical and Analytical Considerations
  • Recommended Reading
  • Chapter 126 - Mixing Studies
  • Method
  • Interpretation
  • Test Performance
  • Sources of Error
  • Quality Assurance
  • Recommended Reading
  • Chapter 127 - Coagulation Factor Testing
  • Methods
  • Test Performance
  • Sources of Error
  • Quality Assurance
  • International Standards
  • Recommended Reading
  • Chapter 128 - Specific Factor Inhibitor Testing
  • Methods and Test Interpretation
  • Sources of Error
  • Recommended Reading
  • Chapter 129 - Laboratory Diagnosis of Lupus Anticoagulant and Anti-Phospholipid Antibodies
  • Testing Indications
  • Test Overview
  • Pre-Analytical Considerations
  • Details of Testing
  • Test Interpretation
  • Sources of Error
  • Recommended Reading
  • Chapter 130 - Laboratory Diagnosis of Inherited von Willebrand Disease
  • Methods
  • Test Interpretation
  • Sources of Error
  • Recommended Reading
  • Chapter 131 - Laboratory Diagnosis of Acquired von Willebrand Syndrome
  • Methods
  • Test Interpretation
  • Sources of Error
  • Recommended Reading
  • Chapter 132 - Laboratory Assessment of Treatment of von Willebrand Disease
  • Methods
  • Treatment Modalities
  • Recommended Reading
  • Chapter 133 - Measurement of Platelet Count, Mean Platelet Volume and Reticulated Platelets
  • Methodology Overview
  • Test Limitations
  • Mean Platelet Volume
  • Reticulated Platelets
  • Recommended Reading
  • Chapter 134 - Platelet Function Analyzer
  • Methods
  • Test Interpretation
  • Sources of Error
  • Quality Assurance
  • Recommended Reading
  • Chapter 135 - Platelet Aggregation Studies
  • Methods
  • Test Interpretation
  • Sources of Error
  • Recommended Reading
  • Chapter 136 - Laboratory Diagnosis of Platelet Function Defects
  • Methods
  • Test Interpretation
  • Recommended Reading
  • Chapter 137 - Antiplatelet Therapy Monitoring
  • Methods
  • Test Interpretation and Sources of Error
  • Recommended Reading
  • Chapter 138 - Laboratory Diagnosis of Heparin-Induced Thrombocytopenia
  • Antigen Assays
  • Platelet Activation (Functional) Assays
  • Recommended Reading
  • Chapter 139 - Laboratory Evaluation of Thrombotic Thrombocytopenic Purpura
  • Measurement of ADAMTS13 Activity
  • Measurement of Anti-ADAMTS13 Autoantibodies
  • Recommended Reading
  • Chapter 140 - Fibrinolytic Testing
  • Physiology
  • Hereditary Fibrinolytic Bleeding
  • Acquired Fibrinolytic Bleeding Disorders
  • Fibrinolytic Thrombosis
  • Recommended Reading
  • Chapter 141 - Laboratory Evaluation of Factor XIII Deficiency
  • FXIII Activity Assays
  • Antigenic Assays
  • Test Limitations
  • Test Interpretation
  • Recommended Reading
  • Chapter 142 - Laboratory Techniques in Fibrinolysis Testing
  • Screening Tests
  • Individual Factor Tests
  • Recommended Reading
  • Chapter 143 - Laboratory Evaluation of Long-Term Thrombophilic Disorders
  • Testing Recommendations
  • Testable Thrombophilia Risk Factors
  • Recommended Reading
  • Chapter 144 - Antithrombin Testing
  • Physiologic Role and Mechanism of Action
  • Congenital AT Deficiency
  • Testing Indications
  • Pre-Analytical Considerations
  • Testing Overview
  • Testing Methodologies
  • Determining the Subtype of Type II AT Deficiency
  • Recommended Reading
  • Chapter 145 - Protein C Deficiency Evaluation
  • Epidemiology and Clinical Presentation
  • Testing Recommendations
  • PC Deficiency Testing Overview
  • Diagnostic Guidelines
  • Protein C Testing Methodologies
  • Limitations of Protein C Testing
  • Test Interpretation
  • Recommended Reading
  • Chapter 146 - Protein S Deficiency Evaluation
  • Physiologic Role
  • Epidemiology
  • Test Recommendations
  • Types of PS Deficiency
  • Diagnostic Guidelines
  • Testing Modalities
  • Test Interpretation
  • Recommended Reading
  • Chapter 147 - Testing for Activated Protein C Resistance
  • Activated Protein C Resistance
  • Recommended Reading
  • Chapter 148 - Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in Inherited Thrombophilia
  • Factor V Leiden
  • Prothrombin Gene Mutation
  • Diagnostic Testing
  • Summary
  • Recommended Reading
  • Chapter 149 - Laboratory Management of Disseminated Intravascular Coagulation
  • Diagnosis of DIC and the Role of Laboratory Testing
  • Test Interpretation
  • Recommended Reading
  • Chapter 150 - Circulating Microparticles
  • Composition of Microparticles
  • Classification of Microparticles
  • Mechanisms of Microparticle Release
  • Role of Microparticles
  • Microparticles in Human Disease
  • Processing of Microparticles
  • Methods for Detection of Microparticles
  • Recommended Reading
  • Chapter 151 - Monitoring of Heparins, Fondaparinux, Direct Thrombin Inhibitors and Oral Anti-Xa Medications
  • Unfractioned Heparin
  • Low Molecular Weight Heparin and Fondaparinux
  • Oral Direct Anti-Xa Inhibitors
  • Direct Thrombin Inhibitors
  • Recommended Reading
  • Chapter 152 - Laboratory Support for Warfarin Monitoring
  • Warfarin Monitoring
  • Abnormal Warfarin Responsiveness
  • Recommended Reading
  • Chapter 153 - Thrombin Generation Assays
  • Assay Methodology Overview
  • Test Interpretation
  • Test Limitations
  • Recommended Reading
  • Chapter 154 - Thromboelastography/Thromboelastometry
  • Principles of Testing
  • Result Interpretation
  • Test Limitations
  • Recommended Reading
  • Abbreviations
  • General Handbook References
  • Index

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

84,43 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung des WebShops erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok